WO2005105731A1 - 新規な結晶性パントテン酸カルシウム - Google Patents
新規な結晶性パントテン酸カルシウム Download PDFInfo
- Publication number
- WO2005105731A1 WO2005105731A1 PCT/JP2005/007968 JP2005007968W WO2005105731A1 WO 2005105731 A1 WO2005105731 A1 WO 2005105731A1 JP 2005007968 W JP2005007968 W JP 2005007968W WO 2005105731 A1 WO2005105731 A1 WO 2005105731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium pantothenate
- crystalline calcium
- crystalline
- powder
- amorphous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a novel crystalline calcium pantothenate.
- Calcium pantothenate (calcium pantothenate: monocalcium bis [(R) -N- (2,4-dihydroxy-3,3-dimethylbutyryl) - ⁇ -ara-nate]]; Is sometimes abbreviated as “PC.”
- An amorphous product of calcium pantothenate is known as an amorphous product.However, since this product is hygroscopic, there is a problem that the powder becomes moist and the powder hardens.
- oc-type, ⁇ -type, and ⁇ -type solvent-free crystals are known as crystal-type solid powders
- 4CH OH-1H-added kamoton crystals and monohydrate crystals are known as solvent-added crystals ( These crystals
- a homogeneous mixture containing crystalline calcium pantothenate and amorphous calcium pantothenate is wetted to produce crystalline pantothenic acid potassium, and the resulting crystal is again amorphous pantothene.
- the mixture is absorbed to produce crystalline calcium pantothenate, and the same process is repeated several times using the obtained crystalline calcium pantothenate to significantly improve fluidity. It has been found that a non-hygroscopic crystalline calcium pantothenate having an improved water content can be produced.
- the obtained crystalline calcium pantothenate has a diffraction angle (2 °) of the main peak with a known ⁇ -type crystal by powder X-ray diffraction, but the peak intensity at 5.1 ° and 16.0 ° is 20 °.
- the peak intensity at 5.1 ° and 16.0 ° is 20 °.
- the present invention has been completed based on the above findings.
- crystalline calcium pantothenate comprising the following steps: (1) preparing a homogeneous mixture by mixing crystalline calcium pantothenate and amorphous calcium pantothenate;
- a crystalline calcium pantothenate obtainable by a method comprising: According to a preferred embodiment of the present invention, in the above step (1), the proportion of the crystalline calcium pantothenate is 30% by weight or more based on the total weight of the homogeneous mixture, and the above-mentioned crystalline calcium pantothenate; The above-mentioned crystalline calcium pantothenate, which can be obtained by using a j8-type crystal as the crystalline calcium pantothenate in the above step (1), is provided.
- the ratio of the diffraction intensity at a diffraction angle (2 ⁇ ) of 5 to the diffraction intensity at a diffraction angle (20) force S16 ° of powder X-ray diffraction is 1 or more.
- crystalline calcium pantothenate is provided in the range of 1 to 3, more preferably in the range of 1.5 to 2.5.
- This crystalline calcium pantothenate can be produced by a method including the above steps (1) to (3), and has diffraction angles (2 °) of 5. and 10.3. , 11.9. , 16.0. , And 18.9 °.
- the ratio of the diffraction intensity at 2 ° of 5.1 ° to the diffraction intensity at 2 ° of 16 ° in powder X-ray diffraction is 1 or more, preferably in the range of 1 to 3, more preferably in the range of 1.5 to 2.5.
- the present invention also provides a crystalline calcium pantothenate, which is a crystalline calcium pantothenate which can be produced by a method comprising the above steps (1) to (3).
- the present invention provides a method for producing crystalline calcium pantothenate, comprising the following steps:
- the crystalline calcium pantothenate of the present invention has excellent fluidity despite its extremely low hygroscopicity and crystallinity, and the non-hygroscopicity and amorphous properties of conventional crystalline calcium pantothenate It has the fluidity of calcium pantothenate in the form. Therefore, the crystalline calcium pantothenate of the present invention has excellent handling and storage properties during storage and use, and is suitable for production on an industrial scale.
- FIG. 1 is a view showing a powder X-ray diffraction pattern of a
- FIG. 2 is an electron micrograph of the ⁇ -type crystal produced in Reference Example 1.
- FIG. 3 is an electron micrograph (enlarged photograph) of the ⁇ -type crystal produced in Reference Example 1.
- FIG. 4 is a view showing an X-ray powder diffraction pattern of a ⁇ -type crystal produced in Reference Example 2.
- FIG. 5 is an electron micrograph of the ⁇ -type crystal produced in Reference Example 2.
- FIG. 6 is an electron micrograph (enlarged photograph) of the ⁇ -type crystal produced in Example 2.
- FIG. 7 is a view showing a change in a powder X-ray diffraction pattern of a product in a repetition step in Example 1.
- ( ⁇ ) shows the powder X-ray diffraction pattern of the
- ⁇ shows the powder X-ray diffraction pattern of the first repetition product
- (C) shows the repetition 2 shows the powder X-ray diffraction pattern of the second product.
- FIG. 8 is a view showing a change in a powder X-ray diffraction pattern of a product in a repetition step in Example 1.
- (D) shows the powder X-ray diffraction pattern of the product after the third repetition
- ( ⁇ ) shows the powder X-ray diffraction pattern of the product after the fourth repetition
- (F) shows the generation of the eighth repetition 3 shows a powder X-ray diffraction pattern of the product.
- FIG. 9 is an electron micrograph of the crystalline calcium pantothenate of the present invention produced in Example 1.
- FIG. 10 is an electron micrograph (enlarged photograph) of the crystalline calcium pantothenate of the present invention produced in Example 1.
- FIG. 11 is an electron micrograph of an amorphous powder.
- FIG. 12 is an electron micrograph (enlarged photo) of an amorphous powder.
- the term "crystalline” refers to the force of a substance that is substantially completely crystalline, the force that includes a substance that contains a small amount of amorphous portion, and that calcium pantothenate is completely amorphous. (State in which no peak can be substantially confirmed by powder X-ray diffraction) is excluded.
- the term “crystalline” should not be interpreted as excluding substances containing a small amount of amorphous parts.
- amorphous means a state in which a peak cannot be substantially confirmed by powder X-ray diffraction.
- non-hygroscopic as used herein means that the moisture absorption after 24 hours at 40 ° C and 75% relative humidity is 2% or less, preferably 1% or less. Then
- the crystalline calcium pantothenate of the present invention comprises the following steps:
- the above step (1) is a step of mixing crystalline calcium pantothenate and amorphous calcium pantothenate to produce a uniform mixture containing crystalline calcium pantothenate and amorphous calcium pantothenate.
- the crystalline calcium pantothenate it is preferable to use non-hygroscopic crystalline calcium pantothenate.
- non-hygroscopic j8-type crystals in the present specification, “j8-type crystals” Chem. Pharm. Bull, 24, pp. 3097-3102, 1976, which means j8-type crystals).
- j8-type crystals in the present specification, “j8-type crystals” Chem. Pharm. Bull, 24, pp. 3097-3102, 1976, which means j8-type crystals.
- the method for producing the amorphous calcium pantothenate used as a raw material is not particularly limited.For example, a method in which an aqueous solution is sprayed and dried with hot air to produce an amorphous powder, or a crystal crystallized from a methanol solution is filtered. After that, a powder produced by a method of producing an amorphous powder by drying with hot air can be suitably used.
- calcium pantothenate used as a raw material has as high a purification degree as possible.
- calcium pantothenate produced by a method such as a synthesis method, a fermentation method, or a method applying genetic recombination technology can be used, and recrystallized or purified by ordinary purification means to obtain crystalline calcium pantothenate or amorphous calcium pantothenate. You can produce calcium pantothenate.
- the method of mixing the crystalline calcium pantothenate with the amorphous calcium pantothenate is not particularly limited, but usually, the crystalline pantothenic acid powder prepared in powder form is mixed with the amorphous calcium pantothenate. It is desirable to produce a uniform mixture by mechanical mixing.
- the particle size of the powder of crystalline calcium pantothenate or amorphous calcium pantothenate used as a raw material is not particularly limited, but is, for example, about 20 to 500 / ⁇ .
- the homogeneous mixture can be prepared by a method commonly used in the art as a means for mixing a solid, preferably a powder.
- the temperature and humidity at the time of preparing the homogeneous mixture are not particularly limited. For example, mixing is performed at room temperature under normal humidity, for example, 40 to 80% RH (% RH indicates a relative humidity. The same applies to the following. )).
- the preparation of the homogeneous mixture can be carried out in an appropriately heated / humidified state, and by doing so, the second step can be carried out simultaneously.
- the mixing ratio of the crystalline calcium pantothenate and the amorphous calcium pantothenate is not particularly limited, and can be appropriately selected by those skilled in the art according to the moisture absorption conditions in the next step, the type of desired crystalline calcium pantothenate, and the like.
- the proportion of crystalline calcium pantothenate may be at least 10% by weight, preferably about 30% by weight, based on the total weight of the homogeneous mixture.
- the crystalline calcium pantothenate obtained in the step (1) is mixed with amorpha.
- This is a step of absorbing a homogeneous mixture containing calcium pantothenate in a state of moisture.
- this moisture absorption step can be performed by allowing the above-mentioned homogeneous mixture to stand at an appropriate temperature and humidity, or by stirring at an appropriate temperature and humidity.
- the temperature and humidity are set to a value sufficient for the amorphous calcium pantothenate to crystallize as non-hygroscopic crystalline calcium pantothenate.
- Example 8 For such temperature and humidity, for example, a test similar to Example 8 described in the example of International Publication WO01 / 98255 is performed according to the type of the homogeneous mixture and the type of the desired non-hygroscopic calcium pantothenate. This can be easily determined by those skilled in the art. For example, an appropriate combination can be selected from a temperature in the range of room temperature to about 80 ° C. and a humidity of about 30 to 90% RH, preferably about 40 to 80% RH.
- means for stirring is not particularly limited, and an ordinary mechanical stirring device can be used. In order to efficiently produce the target product on an industrial scale, stirring is generally essential.
- the term “stirring” as used herein includes the most commonly used means of achieving the same physical effect as stirring, such as vibration, flow, ultrasonic stirring, etc. It needs to be interpreted in a broad sense.
- the non-hygroscopic crystalline calcium pantothenate obtained in the above step (2) is preferably a crystalline substance substantially composed of non-hygroscopic crystalline calcium pantothenate and substantially free of an amorphous portion. It is preferably prepared.
- non-hygroscopic crystalline calcium pantothenate containing a different kind of crystalline calcium pantothenate than the crystalline calcium pantothenate used to prepare the homogeneous mixture may be obtained.
- j8-type crystals are obtained.
- the crystalline calcium pantothenate obtained in the above step (2) may be used as a raw material in the step (3) without performing a treatment such as drying, but if necessary, after drying, the step (3) May be used as a raw material.
- the drying means is not particularly limited, and drying can be performed under appropriate conditions using a dryer available in the art.
- the above step (3) is a step of repeating the above steps (1) and (2) using the crystalline calcium pantothenate obtained in the above step (2) as a raw material.
- This step can be performed in the same manner as in the method described above.
- the number of repetitions is not particularly limited, but at least once. It is preferably at least 2 times, more preferably at least 5 times, particularly preferably at least 8 times. Although the upper limit of the number of repetitions is not particularly limited, the effect of improving the fluidity may be reduced by more than 10 repetitions, and therefore is about 10 or less from the viewpoint of industrial production cost.
- the crystalline calcium pantothenate of the present invention has a characteristic peak pattern in powder X-ray diffraction, and is characterized by being non-hygroscopic and having fluidity comparable to that of an amorphous form. And
- the crystalline calcium pantothenate of the present invention has diffraction angles (20) of 5. and 10.3 in powder X-ray diffraction. , 11.9. , 16.0.
- a diffraction angle (2 0) 5.1 diffraction angle (2 theta) ratio of the diffraction intensity 1 16 ° in 16.0 ° with respect to the diffraction intensity I 5 ⁇ 1 in ° ( I 16 Q / I 51 ) is 1 or more, preferably in the range of 1 to 3 (the numerical range indicated by “from” in the present specification is a range including the lower limit and the upper limit), more preferably It ranges from 1.5 to 2.5.
- “type 13 crystal” is known (Chem. Pharm. Bull, 24, pp. 3097-3102, 1976), and this crystal has a diffraction intensity I 5 ⁇ at a diffraction angle (20) of 5.1 °.
- a diffraction angle (2 theta) of less than the ratio of the diffraction intensity 1 16 ° in 16.0 ° (I 16 Q / I 5 1) is 1 for 1, and crystalline pantothenate force Rushiumu of the present invention can be clearly distinguished.
- the value of the diffraction angle 2 2 in the powder X-ray diffraction measurement is the angle when the ⁇ characteristic X-ray of copper, which is commonly used, is used, and the accuracy of the angle is about ⁇ 0.1 °.
- the crystalline calcium pantothenate of the present invention also differs in appearance from the j8-type crystal. And resembles amorphous form of pantothenic acid. Based on these appearance characteristics, the crystalline calcium pantothenate of the present invention has remarkably improved fluidity as compared with the acicular ⁇ -type crystal, and has excellent fluidity similar to that of amorphous calcium pantothenate. have. In addition, the crystalline calcium pantothenate of the present invention has the characteristics of non-hygroscopicity and is superior to the amorphous form of calcium pantothenate. Combines the advantages of calcium pantothenate.
- step (3) the ability to obtain the desired crystalline calcium pantothenate of the present invention without performing any treatment such as drying is provided.
- it can be subjected to an appropriate treatment such as drying and sizing if necessary.
- the drying means is not particularly limited, and drying can be performed under appropriate conditions using a dryer available in the art.
- the crystalline calcium pantothenate of the present invention can be used as a pharmaceutical, and can be used as a quasi-drug, cosmetics, processed food, animal feed, or a composition preliminarily prepared for the purpose of producing them. Can be appropriately blended. In such a use form, the crystalline calcium pantothenate of the present invention has good stability and does not impair the stability of other components. In addition, when preparing an aqueous solution, the crystalline calcium pantothenate powder of the present invention is finely dispersed in water as compared with the amorphous calcium pantothenate powder, so that the time until uniform dissolution is reduced, Example that reduces the work load
- Rigaku Corporation MultiFlex 2kw (horizontal goometer) was used as a powder X-ray diffractometer, and the following conditions were used for X-ray diffraction measurement.
- Monochromatic X-ray Monochromator method + PHA (Pulse height analyzer Differential mode)
- sample changer ASC-6A
- the sample holder used was a through hole type sample plate filled with 0.8 g of sample or a sample plate (bottom deep type depth about 2 mm). Transfer the entire amount of the sample from the stationary container to a mortar, and Grinding was performed until the body was rough and free of grains, and the samples were handled and filled into each sample holder according to the method described in the instruction manual.
- the setting magnification is about 200 times and about 2000 times.
- the powder properties were measured using a powder tester PT-N type manufactured by Hosokawa Micron Corporation, and each measurement was performed three times by a very general method according to the procedure manual, and the average value was adopted.
- the amorphous powder of calcium pantothenate was obtained by drying an aqueous solution of calcium pantothenate with a spray drier.
- ⁇ -type crystalline calcium pantothenate was obtained.
- 5 g of amorphous pantothenate granulated product (manufactured by Daiichi Fine Chemical Co., Ltd.) was thoroughly dissolved in 100 g of 10 wt% aqueous ethanol with sufficient stirring, and allowed to stand at 25 ° C.
- the precipitated crystals were filtered under reduced pressure and dried under reduced pressure at room temperature.
- Example 1 Production of crystalline calcium pantothenate of the present invention
- the j8-type crystal used first, the crystalline calcium pantothenate obtained in the first operation, the crystalline pantothenic acid lucidum obtained in the second operation, obtained in the third operation 7 and 8 show powder X-ray diffraction charts of the crystalline calcium pantothenate obtained, the crystalline calcium pantothenate obtained by the fourth operation, and the crystalline calcium pantothenate obtained by the eighth operation.
- this crystalline calcium pantothenate has a needle-like shape having corners peculiar to crystals of several tens of meters or more. Almost no crystals are contained, and the appearance is similar to that of the amorphous powder (Figs. 11 and 12). Was presented.
- the initial moisture content of the crystalline calcium pantothenate obtained in Example 1 was measured using a Karl-Fischer moisture meter and found to be 0.96%. 1 g of this crystalline pantothenic acid was accurately weighed, spread in a weighing bottle, and allowed to stand in a constant temperature and humidity machine at 40 ° C and 75% RH for 24 hours to determine the weight increase. was 0.54%.
- a similar test confirmed the hygroscopicity of the amorphous powder, which was the raw material, and found that this powder had an initial water content of 2.11% and an increase in water content of 5.71%. The amorphous powder after the test had collapsed due to deliquescence, and did not retain its original shape. From the above results, it was a component that the crystalline calcium pantothenate of the present invention was non-hygroscopic.
- Example 2 The powder physical properties of the crystalline calcium pantothenate obtained in Example 1 above were examined. As a control, the
- the specific gravity is an important factor when filling a container as a product, and the larger the specific gravity, the smaller the container.
- Compressibility is a physical property determined by (solid apparent specific gravity-loose apparent specific gravity) / solid apparent specific gravity, and indicates the degree of bulk reduction obtained from the difference in bulk density between loosely packed and densely packed. The larger this number is, the lower the fluidity is, and the outlet such as a hopper is blocked. I'm sorry.
- the collapse angle is the angle of the slope formed by the sediment remaining after collapse by applying a certain impact to the conical powder compact when measuring the angle of repose. The larger the angle of repose and the collapse angle, the lower the fluidity It indicates that.
- the difference between the angle of repose and the angle of collapse is called the angle of difference, and the larger this angle is, the higher the flushing performance.
- Flushing is a phenomenon in which a powder or the like containing a lot of air suddenly has a high fluidity like a liquid, and the flow rate of the powder is not controlled and a jet flows.
- the spatula angle is the angle of inclination of the side when a metal spatula (spatula) is leveled and powder is deposited on it, and it can be considered as the discharge angle of repose. This is a large value.
- the needle-shaped / 3-type crystal has a lower specific gravity than that of an amorphous powder, and thus has poor fluidity.
- needle-like ⁇ -type crystals are highly likely to cause flashing, which has strong adhesion. This property is a very serious problem when producing calcium pantothenate or when it is distributed as a product and used in medical settings.
- the crystalline calcium pantothenate of the present invention has powder properties comparable to those of the amorphous powder, and it is clear that the handleability during production and use is excellent.
- the crystalline calcium pantothenate of the present invention has excellent fluidity despite its extremely low hygroscopicity and crystallinity, and the non-hygroscopic and amorphous properties of conventional crystalline calcium pantothenate It has the fluidity of calcium pantothenate in the form. Therefore, the crystalline calcium pantothenate of the present invention has excellent handling and storage properties during storage and use, and is suitable for production on an industrial scale.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512796A JPWO2005105731A1 (ja) | 2004-04-30 | 2005-04-27 | 新規な結晶性パントテン酸カルシウム |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-135092 | 2004-04-30 | ||
JP2004135092 | 2004-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005105731A1 true WO2005105731A1 (ja) | 2005-11-10 |
Family
ID=35241602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/007968 WO2005105731A1 (ja) | 2004-04-30 | 2005-04-27 | 新規な結晶性パントテン酸カルシウム |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2005105731A1 (ja) |
CN (1) | CN1950330A (ja) |
WO (1) | WO2005105731A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005325080A (ja) * | 2004-05-17 | 2005-11-24 | Daiichi Fine Chemical Co Ltd | パントテン酸カルシウム及びビタミン類を含む組成物 |
JP2007238852A (ja) * | 2006-03-10 | 2007-09-20 | Toyo Ink Mfg Co Ltd | 微細有機顔料の製造方法 |
JP2010534700A (ja) * | 2007-07-31 | 2010-11-11 | ディーエスエム アイピー アセッツ ビー.ブイ. | Na−ベータ−アラニネートおよびカルシウムパントテネートの合成方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640852B (zh) * | 2018-06-11 | 2020-12-25 | 精晶药业股份有限公司 | 一种调节d-泛酸钙松密度和粒度的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000039076A1 (fr) * | 1998-12-25 | 2000-07-06 | Fuji Chemical Industries, Ltd. | Procede de production de pantothenate de calcium |
WO2001098255A1 (fr) * | 2000-06-23 | 2001-12-27 | Daiichi Fine Chemical Co., Ltd | Procede de production de pentothenate de calcium |
-
2005
- 2005-04-27 WO PCT/JP2005/007968 patent/WO2005105731A1/ja active Application Filing
- 2005-04-27 CN CNA2005800138491A patent/CN1950330A/zh active Pending
- 2005-04-27 JP JP2006512796A patent/JPWO2005105731A1/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000039076A1 (fr) * | 1998-12-25 | 2000-07-06 | Fuji Chemical Industries, Ltd. | Procede de production de pantothenate de calcium |
WO2001098255A1 (fr) * | 2000-06-23 | 2001-12-27 | Daiichi Fine Chemical Co., Ltd | Procede de production de pentothenate de calcium |
Non-Patent Citations (1)
Title |
---|
INAGAKI M. ET AL: "Crystal Forms of Calcium D(+) -Pantithehate.", CHEM PHARM BULL., vol. 24, no. 12, 1976, pages 3097 - 3102 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005325080A (ja) * | 2004-05-17 | 2005-11-24 | Daiichi Fine Chemical Co Ltd | パントテン酸カルシウム及びビタミン類を含む組成物 |
JP2007238852A (ja) * | 2006-03-10 | 2007-09-20 | Toyo Ink Mfg Co Ltd | 微細有機顔料の製造方法 |
JP2010534700A (ja) * | 2007-07-31 | 2010-11-11 | ディーエスエム アイピー アセッツ ビー.ブイ. | Na−ベータ−アラニネートおよびカルシウムパントテネートの合成方法 |
JP2014098003A (ja) * | 2007-07-31 | 2014-05-29 | Dsm Ip Assets Bv | Na−ベータ−アラニネートおよびカルシウムパントテネートの合成方法 |
JP2016047833A (ja) * | 2007-07-31 | 2016-04-07 | ディーエスエム アイピー アセッツ ビー.ブイ. | Na−ベータ−アラニネートおよびカルシウムパントテネートの合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1950330A (zh) | 2007-04-18 |
JPWO2005105731A1 (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dhumal et al. | Ultrasound assisted engineering of lactose crystals | |
WO2015072494A1 (ja) | 新規二酢酸ナトリウム結晶及び該結晶を含有する固形透析用製剤 | |
CN107406455A (zh) | 3,5‑二取代的苯炔基化合物晶体 | |
Yadav et al. | SOLVENT DIFFUSION (ESD) TECHNIQUE. | |
WO2005105731A1 (ja) | 新規な結晶性パントテン酸カルシウム | |
US20120301520A1 (en) | Directly compressible magnesium hydroxide carbonate | |
BR112019006310B1 (pt) | Método para fabricar digliceróxido de cálcio | |
WO2011128413A1 (en) | Process for the production of polymorph form i of agomelatine | |
CN104804054B (zh) | 一种索氟布韦的晶型及其应用 | |
Prasad et al. | Basics of crystallization process applied in drug exploration | |
JP2005325080A (ja) | パントテン酸カルシウム及びビタミン類を含む組成物 | |
CN109265355A (zh) | 戊二胺辛二酸盐及其晶体 | |
CN108727387A (zh) | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 | |
JPH04228420A (ja) | 塩基性炭酸マグネシウム及びその製造方法 | |
PL169722B1 (pl) | Sposób mikronizacji 1-hydroksy-2-naftalenokarboksylanowej soli 4-hydroksy-a1 [[[6-(4- fenylobutoksy)-heksylo]amino]metylo]-1,3-benzenodimetanolu PL PL PL | |
US20060078573A1 (en) | Methods of modifying crystal habit | |
WO2003037907A1 (fr) | Cristaux de maltitol contenant des cristaux d'un saccharide autre que le maltitol et procede de production de ces cristaux | |
Salunke et al. | Floating microcarriers of an antidiabetic drug: Preparation and its in-vitro evaluation | |
JP6667639B2 (ja) | γ−アミノ酪酸半水和物結晶及びその製造方法 | |
WO2001098255A1 (fr) | Procede de production de pentothenate de calcium | |
EP3636282A1 (en) | Pharmaceutical ingredient carrier and method for producing same | |
CN110384673A (zh) | 右旋奥拉西坦胶囊及其制备方法 | |
WO2018209667A1 (zh) | 多环杂环化合物的晶型、其制备方法、应用及组合物 | |
CN117486789A (zh) | 一种托拉塞米共晶盐及其制备方法和应用 | |
JP5594670B2 (ja) | 液−液界面を利用する被覆型複合物質の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512796 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580013849.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |